Tocilizumab has no clinically relevant effects on methotrexate pharmacokinetics in patients with rheumatoid arthritis

International Journal of Clinical Pharmacology and Therapeutics

Volumn 50, Issue 3, 2012, Pages 218-223

  Schmitt, Christophe ^a   Kuhn, Barbara ^a   Zhang, Xiaoping ^b   Kivitz, Alan ^c   Grange, Susan ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b HOFFMANN LA ROCHE INC   (United States)

^c Altoona Center for Clinical Research   (United States)

Author keywords

Drug interactions; Inflammation; Methotrexate; Monoclonal antibodies; Pharmacokinetics; Rheumatoid arthritis

Indexed keywords

7 HYDROXYMETHOTREXATE; C REACTIVE PROTEIN; METHOTREXATE; TOCILIZUMAB;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; RHEUMATOID ARTHRITIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED;

EID: 84863140901     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201613     Document Type: Article

References (16)

1. Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev. 2005; 57: 163-172. doi:10.1124/pr.57.2.3 PubMed (Pubitemid 41043882)
2. Shen DD, Azarnoff DL. Clinical pharmacokinetics of methotrexate. Clin Pharmacokinet. 1978; 3: 1-13. doi:10.2165/00003088-197803010-00001 PubMed (Pubitemid 8287271)
3. Edelman J, Biggs DF, Jamali F, Russell AS. Low-dose methotrexate kinetics in arthritis. Clin Pharmacol Ther. 1984; 35: 382-386. doi:10.1038/clpt.1984.47 PubMed (Pubitemid 14174145)
4. Seideman P, Beck O, Eksborg S, Wennberg M. The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis. Br J Clin Pharmacol. 1993; 35: 409-412. PubMed (Pubitemid 23103382)
5. Elsby R, Fox L, Stresser D, Layton M, Butters C, Sharma P, Smith V, Surry D. In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug-drug interaction with methotrexate. Eur J Pharm Sci. 2011; 43: 41-49. doi:10.1016/j.ejps.2011.03.006 PubMed
6. Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, Matsumoto Y, Ohsugi Y. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005; 5: 1731-1740. doi:10.1016/j.intimp.2005.05. 010 PubMed (Pubitemid 41116745)
7. Schmitt C, Kuhn B, Zhang X, Kivitz AJ, Grange S. Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2011; 89: 735-740. doi:10.1038/clpt.2011.35 PubMed
8. Nishimoto N, Yoshizaki K, Maeda K, Kuritani T, Deguchi H, Sato B, Imai N, Suemura M, Kakehi T, Takagi N, Kishimoto T. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J Rheumatol. 2003; 30: 1426-1435. PubMed (Pubitemid 36835435)
9. Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, Vernon E, Ambs P, FleischmannR. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum. 2011; 63: 609-621. doi:10.1002/art.30158 PubMed
10. Hushaw LL, Sawaqed R, Sweis G, Reigle J, Gopal A, Brandt D, Sweis N, Curran J, Niewold TB, Sweiss NJ. Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis. Ther Clin Risk Manag. 2010; 6: 143-152. PubMed
11. RoACTEMRA® (tocilizumab). Summary of Product Characteristics. Grenzach-Wyhlen. Germany: Roche Pharma AG. http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR---Product- Information/human/000955/WC500054890.pdf. January 2009.
12. Kulmatycki KM, Jamali F. Drug disease interactions: role of inflammatory mediators in disease and variability in drug response. J Pharm Pharm Sci. 2005; 8: 602-625. PubMed
13. Aitken AE, Richardson TA, Morgan ET. Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol. 2006; 46: 23-49. doi:10.1146/annurev.pharmtox.46.120604.141059
14. Hartmann G, Cheung AK, Piquette-Miller M. Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia. J Pharmacol Exp Ther. 2002; 303: 273-281. doi:10.1124/jpet.102. 039404 PubMed
15. FDA Guidance for Industry. Bioavailability and bioequivalence studies for orally administered drug products - general considerations. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm070124.pdf. March 2003.
16. Frey N, Grange S, Woodworth T. Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis. J Clin Pharmacol. 2010; 50: 754-766. doi:10.1177/0091270009350623PubMed